Frances Tulley

Frances Tulley is a disruptive leader and passionate advocate for the pharmaceutical industry, partnering with healthcare systems to enhance patient care beyond medicines development. She has spoken publicly, including delivering the keynote address at Reuters Customer Engagement Europe. 

Frances leads a portfolio of rare disease medicines for Alexion, AstraZeneca Rare Diseases UKI – turning around an underperforming business and doubling revenues in 2024 with innovative approaches including ‘AI case finding’ to accelerate diagnosis of rare diseases. She chairs the “Performance & Growth” Leadership Team, accountable for performance monitoring across the UK rare disease portfolio, allocation of budget, approval of strategic plans and oversight of pipeline product launch governance. 

Beginning her career in management consulting with Accenture, Frances consistently ranked as a top performer. As the European Lead for Competitive Strategies and Launch Excellence, she redefined growth strategies and led enterprise transformations with measurable EBITDA impact. 

 Frances applied her skills to community building as Vice Chair of Trustees for Sunday Assembly, supporting people to “Live Better, Help Often and Wonder More’. As a Marketing Academy Leadership Programme Scholar, Frances aspires to be an ethical, purpose-driven leader, believing success comes from energised teams who feel safe to innovate and take risks.